NZ597600A - Glycopolysialylation of non-blood coagulation proteins - Google Patents

Glycopolysialylation of non-blood coagulation proteins

Info

Publication number
NZ597600A
NZ597600A NZ597600A NZ59760010A NZ597600A NZ 597600 A NZ597600 A NZ 597600A NZ 597600 A NZ597600 A NZ 597600A NZ 59760010 A NZ59760010 A NZ 59760010A NZ 597600 A NZ597600 A NZ 597600A
Authority
NZ
New Zealand
Prior art keywords
psa
mpsa
glycoprotein
blood coagulation
aminooxy
Prior art date
Application number
NZ597600A
Other languages
English (en)
Inventor
Sanjay Jain
Gregory Gregoriadis
Archana Dwivedi
Srijit Nath
Juergen Siekmann
Stefan Haider
Hanspeter Rottensteiner
Peter Turecek
Original Assignee
Lipoxen Technologies Ltd
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd, Baxter Int, Baxter Healthcare Sa filed Critical Lipoxen Technologies Ltd
Priority to NZ623810A priority Critical patent/NZ623810A/en
Publication of NZ597600A publication Critical patent/NZ597600A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ597600A 2009-07-27 2010-07-26 Glycopolysialylation of non-blood coagulation proteins NZ597600A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ623810A NZ623810A (en) 2009-07-27 2010-07-26 Glycopolysialylation of non-blood coagulation proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22882809P 2009-07-27 2009-07-27
US34713610P 2010-05-21 2010-05-21
PCT/GB2010/001422 WO2011012850A2 (en) 2009-07-27 2010-07-26 Glycopolysialylation of non-blood coagulation proteins

Publications (1)

Publication Number Publication Date
NZ597600A true NZ597600A (en) 2014-05-30

Family

ID=46582461

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ597600A NZ597600A (en) 2009-07-27 2010-07-26 Glycopolysialylation of non-blood coagulation proteins

Country Status (12)

Country Link
US (1) US9795683B2 (enExample)
EP (2) EP3081233B1 (enExample)
JP (1) JP5909755B2 (enExample)
KR (1) KR101912335B1 (enExample)
CN (1) CN102573920B (enExample)
AU (3) AU2010277438B2 (enExample)
CA (1) CA2769244A1 (enExample)
ES (1) ES2590679T3 (enExample)
NZ (1) NZ597600A (enExample)
RU (1) RU2533619C2 (enExample)
SG (1) SG178051A1 (enExample)
WO (1) WO2011012850A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
AU2010281453C1 (en) 2009-07-27 2019-08-15 Takeda Pharmaceutical Company Limited Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
DK2598172T3 (da) * 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse
AU2015275284C1 (en) * 2010-07-30 2018-04-05 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
WO2012159084A1 (en) 2011-05-18 2012-11-22 Baxter International, Inc. Modification-dependent activity assays
EP3808378A1 (en) 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
CN104661685A (zh) 2012-10-15 2015-05-27 诺和诺德保健Ag（股份有限公司） 因子vii缀合物
CZ305153B6 (cs) * 2014-03-11 2015-05-20 Contipro Biotech S.R.O. Konjugáty oligomeru kyseliny hyaluronové nebo její soli, způsob jejich přípravy a použití
CN106488933A (zh) * 2014-03-31 2017-03-08 韩美药品株式会社 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法
MA45473A (fr) 2016-04-04 2019-02-13 Shire Human Genetic Therapies Inhibiteur de c1 estérase conjugué et ses utilisations
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
SG11202107497XA (en) 2019-01-23 2021-08-30 Regeneron Pharma Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
CN112129946A (zh) * 2020-08-16 2020-12-25 陆修委 无糖链型惰性蛋白封闭剂的制备方法及应用
EP4298219A1 (en) 2021-02-26 2024-01-03 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4966999A (en) 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
SE466754B (sv) 1990-09-13 1992-03-30 Berol Nobel Ab Saett att kovalent binda biopolymerer till hydrofila ytor
CA2073511A1 (en) 1990-11-14 1992-05-29 Matthew R. Callstrom Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
CA2101918A1 (en) * 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
NZ256921A (en) 1992-10-02 1996-05-28 Pharmacia Ab Formulations of coagulation factor viii and a non-ionic surfactant and their preparation
NO934477L (no) * 1992-12-09 1994-06-10 Ortho Pharma Corp PEG hydrazon- og PEG oksim-bindingdannende reagenser og proteinderivater derav
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
AU6029594A (en) * 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE516173C2 (sv) * 1993-02-16 2001-11-26 Ericsson Telefon Ab L M Anordning för telekommunikation
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
WO1996040731A1 (en) 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Pegylated modified proteins
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
WO1998055607A2 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
AU2051899A (en) 1997-12-03 1999-06-16 Roche Diagnostics Gmbh Method for preparing polypeptides with appropriate glycosilation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6552167B1 (en) 1998-08-28 2003-04-22 Gryphon Therapeutics, Inc. Polyamide chains of precise length
CA2345138C (en) 1998-10-16 2009-12-15 Biogen, Inc. Polymer conjugates of interferon beta-1a and their uses
DE19852729A1 (de) 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
ATE365052T1 (de) 1999-02-22 2007-07-15 Univ Connecticut Neue albuminfreie faktor viii formulierungen
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7230081B1 (en) 1999-11-12 2007-06-12 Maxygen Holdings, Ltd. Interferon gamma conjugates
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
JP4455802B2 (ja) 2000-05-03 2010-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト第ｖｉｉ凝固因子変異型
JP5090605B2 (ja) 2000-05-03 2012-12-05 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子ｖｉｉの皮下投与
ES2256234T3 (es) 2000-05-16 2006-07-16 Lipoxen Technologies Limited Derivatizacion de proteinas en solucion acuosa.
JP2003535208A (ja) 2000-06-08 2003-11-25 ラ ホヤ ファーマシューティカル カンパニー 高分子量ポリエチレン・オキシドを含む多価プラットホーム分子
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
WO2002022776A2 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
DE60137950D1 (de) 2000-10-02 2009-04-23 Novo Nordisk Healthcare Ag Verfahren zur herstellung vitamin-k-abhängiger proteine
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
WO2002077218A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
DK2322229T3 (en) 2001-10-10 2017-03-27 Novo Nordisk As Remodeling and Glycoconjugation of Factor IX
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
KR100948532B1 (ko) 2001-11-07 2010-03-23 넥타르 테라퓨틱스 분지형 중합체 및 그의 공액체
JP2005510229A (ja) 2001-11-28 2005-04-21 ネオーズ テクノロジーズ， インコーポレイテッド アミダーゼを用いる糖タンパク質のリモデリング
ATE405669T1 (de) 2001-11-28 2008-09-15 Neose Technologies Inc Remodellierung von glycoproteinen unter verwendung von endoglycanasen
DK1517710T3 (da) 2002-06-21 2011-07-18 Novo Nordisk Healthcare Ag Pegylerede faktor VII-glycoformer
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
DE02020425T1 (de) * 2002-09-11 2004-07-15 Fresenius Kabi Deutschland Gmbh Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
CA2496317C (en) 2002-09-11 2014-02-18 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
JP4490369B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション マレアミド酸ポリマー誘導体及びこれらの生物学的複合体
DK1596887T3 (da) 2003-02-26 2022-06-20 Nektar Therapeutics Polymer-Faktor VIII-konjugat
ES2512499T3 (es) 2003-04-08 2014-10-24 Yeda Research And Development Co., Ltd. Fármacos pegilados reversibles
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
TWI356065B (en) * 2003-08-08 2012-01-11 Fresenius Kabi De Gmbh Method of producing hydroxyalkyl starch derivative
WO2005014049A2 (en) 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
JP2007501870A (ja) * 2003-08-08 2007-02-01 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒドロキシアルキルデンプンとｇ−ｃｓｆの複合体
US20080206182A1 (en) * 2003-08-08 2008-08-28 Fresenius Kabi Deutschland Gmbh Conjugates of a Polymer and a Protein Linked by an Oxime Group
EP1654290B1 (en) * 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
RU2327703C2 (ru) * 2003-08-12 2008-06-27 Лайпоксен Текнолоджиз Лимитед Производные полисиаловой кислоты
BRPI0417341A (pt) 2003-12-03 2007-04-17 Neose Technologies Inc fator ix glicopeguilado
US7981871B2 (en) * 2003-12-04 2011-07-19 University Of Utah Research Foundation Modified macromolescules and associated methods of synthesis and use
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
WO2006020372A2 (en) 2004-07-23 2006-02-23 Neose Technologies, Inc. Enzymatic modification of glycopeptides
JP2008507990A (ja) 2004-08-02 2008-03-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｆｖｉｉの抱合体
ES2640767T3 (es) 2004-08-12 2017-11-06 Lipoxen Technologies Limited Fraccionamientodepolisacáridos cargados
CN101039965A (zh) * 2004-08-12 2007-09-19 利普生技术有限公司 唾液酸衍生物
ES2593318T3 (es) * 2004-08-12 2016-12-07 Lipoxen Technologies Limited Derivados de ácido siálico
NZ555032A (en) 2004-11-12 2010-02-26 Bayer Healthcare Llc Site-directed modification of FVIII
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
WO2006074279A1 (en) 2005-01-06 2006-07-13 Neose Technologies, Inc. Glycoconjugation using saccharyl fragments
WO2006090119A1 (en) 2005-02-23 2006-08-31 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1919498A2 (en) 2005-08-26 2008-05-14 Maxygen Holdings Ltd. Liquid factor vii composition
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
KR20080108147A (ko) * 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US20090285780A1 (en) 2006-05-24 2009-11-19 Chyi Lee Peg linker compounds and biologically active conjugates thereof
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
SI2049692T1 (sl) 2006-07-13 2016-04-29 Serum Institute Of India Ltd Postopek za pripravo polisialične kisline visoke čistosti
EP2043692B1 (en) 2006-07-25 2016-05-18 Lipoxen Technologies Limited Polysaccharide derivatives of erythropoietin
EP2059527B1 (en) * 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Modified glycoproteins
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
WO2008081024A1 (en) 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
CN102978185B (zh) * 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
CN101778937A (zh) * 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
BRPI0813772A2 (pt) 2007-06-26 2014-12-30 Baxter Int Composto, processo para a preparação de um composto, e, conjugado
US9333247B2 (en) 2007-07-03 2016-05-10 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
BRPI0818288A2 (pt) 2007-10-09 2015-04-14 Polytherics Ltd Proteínas conjugadas e peptídeos.
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
WO2009130602A2 (en) 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
WO2009141418A1 (en) 2008-05-23 2009-11-26 Novo Nordisk A/S Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative
CN102083459A (zh) 2008-05-23 2011-06-01 诺沃-诺迪斯克保健股份有限公司 包括含有peg化的gla-结构域的蛋白质的低粘度组合物
EP2297330A4 (en) 2008-06-04 2012-03-14 Bayer Healthcare Llc FVII MUTINES FOR THE TREATMENT OF MORBUS WILLEBRAND
KR101763559B1 (ko) 2008-07-21 2017-08-14 폴리테릭스 리미티드 생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법
WO2010062768A1 (en) 2008-11-03 2010-06-03 Bayer Healthcare Llc Method for the treatment of hemophilia
US20120121613A1 (en) 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
CN102333788A (zh) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
US20100330033A1 (en) 2009-04-16 2010-12-30 Nian Wu Protein-carrier conjugates
GB0908393D0 (en) 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
AU2010281453C1 (en) 2009-07-27 2019-08-15 Takeda Pharmaceutical Company Limited Blood coagulation protein conjugates
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
KR20120060209A (ko) 2009-07-31 2012-06-11 바이엘 헬스케어 엘엘씨 변형된 인자 ｉｘ 폴리펩티드 및 그의 용도
DE102009028526A1 (de) 2009-08-13 2011-02-24 Leibniz-Institut Für Polymerforschung Dresden E.V. Verfahren zur Modifikation und Funktionalisierung von Sacchariden
WO2011037896A2 (en) 2009-09-25 2011-03-31 Vybion, Inc. Polypeptide modification
CN102639553A (zh) 2009-11-24 2012-08-15 诺沃—诺迪斯克保健股份有限公司 纯化聚乙二醇化蛋白质的方法
CN102770449B (zh) 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP2640483A1 (en) 2010-11-15 2013-09-25 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
JP2014522838A (ja) 2011-07-08 2014-09-08 バイオジェン アイデック ヘモフィリア インコーポレイテッド 第ｖｉｉｉ因子キメラおよびハイブリッドポリペプチドならびにその使用法

Also Published As

Publication number Publication date
CA2769244A1 (en) 2011-02-03
JP5909755B2 (ja) 2016-04-27
RU2533619C2 (ru) 2014-11-20
AU2010277438A1 (en) 2012-02-09
KR101912335B1 (ko) 2018-10-26
WO2011012850A3 (en) 2011-04-14
WO2011012850A2 (en) 2011-02-03
JP2013500375A (ja) 2013-01-07
KR20170085606A (ko) 2017-07-24
WO2011012850A9 (en) 2011-05-12
SG178051A1 (en) 2012-03-29
RU2012106654A (ru) 2013-09-10
US9795683B2 (en) 2017-10-24
CN102573920A (zh) 2012-07-11
AU2010277438B2 (en) 2015-08-20
AU2017265005A1 (en) 2017-12-07
EP2459226B1 (en) 2016-06-29
CN102573920B (zh) 2015-01-14
EP3081233B1 (en) 2020-12-23
ES2590679T3 (es) 2016-11-23
EP3081233A1 (en) 2016-10-19
AU2015242970A1 (en) 2015-11-05
EP2459226A2 (en) 2012-06-06
US20110027350A1 (en) 2011-02-03
AU2015242970B2 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
NZ597600A (en) Glycopolysialylation of non-blood coagulation proteins
NZ623810A (en) Glycopolysialylation of non-blood coagulation proteins
NZ598056A (en) Blood coagulation protein conjugates
EA025738B9 (ru) Способ конъюгирования водорастворимого полимера с терапевтическим белком (варианты) и полученный модифицированный белок (варианты)
MX2023010485A (es) Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
HRP20141083T1 (hr) Konjugati faktora viii i polimera
EP2288715A4 (en) HUMANSERUMALBUMIN-LINKER AND CONJUGATE THEREOF
NZ724828A (en) Nucleophilic catalysts for oxime linkage
EP4406612A3 (en) Anti-cd70 antibody drug conjugates
WO2010135437A3 (en) Multi-lumen cannula
WO2009044273A3 (en) Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2006132670A3 (en) Auristatins having an aminobenzoic acid unit at the n terminus
MY169767A (en) Needle safety device
UA110323C2 (en) Derivative of serum amyloid p and their receipt and application
UA91575C2 (ru) Дендример-пег с четырьмя ветвями для коньюгирования с белками и пептидами
WO2006033107A3 (en) In vivo device for assisting and improving diastolic ventricular function
WO2010014258A3 (en) Conjugates having a releasable linkage
CN102723241B (zh) 继电器的动簧片
TW200744167A (en) Dual-transistor package body
ATE548090T1 (de) Miniaturbahn mit bahnelementen und verbindungselementen
CN202695321U (zh) 继电器的动簧片
US20130247712A1 (en) Crank mechanism
Logue Strategy for eradicating BVD from Scotland
MATSUI et al. Identification of the proteins binding to the BRCT domain of 53BP1
TH104859A (th) ของผสมเส้นใยสำหรับโรคเด็ก

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 JUL 2017 BY SHELSTON IP

Effective date: 20140902

ASS Change of ownership

Owner name: LIPOXEN TECHNOLOGIES LIMITED, GB

Effective date: 20160609

Owner name: BAXALTA GMBH, CH

Effective date: 20160609

Owner name: BAXALTA INC, US

Effective date: 20160609

LAPS Patent lapsed